Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

S Peters; U Dafni; M Boyer; D De Ruysscher; C Faivre-Finn; E Felip; P Garrido; N Girard; M Guckenberger; J Haanen; C Le Pechoux; F Mornex; M Ozsahin; L Paz-Ares; D Planchard; D Raben; S Ramalingam; M Reck; E Smit; R Stahel; A Stenzinger; C Swanton; S Vallone; M C Garassino

doi:10.1093/annonc/mdy553

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

Ann Oncol. 2019 Feb 1;30(2):161-165. doi: 10.1093/annonc/mdy553.

Authors

S Peters¹, U Dafni², M Boyer³, D De Ruysscher⁴, C Faivre-Finn⁵, E Felip⁶, P Garrido⁷, N Girard⁸, M Guckenberger⁹, J Haanen¹⁰, C Le Pechoux¹¹, F Mornex¹², M Ozsahin¹³, L Paz-Ares¹⁴, D Planchard¹⁵, D Raben¹⁶, S Ramalingam¹⁷, M Reck¹⁸, E Smit¹⁹, R Stahel²⁰, A Stenzinger²¹, C Swanton²², S Vallone²³, M C Garassino²⁴

Affiliations

¹ Oncology Department, Lausanne University and CHUV, Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.
² Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
³ Chris O'Brien Lifehouse, Camperdown, Australia.
⁴ GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Department of Radiation Oncology (Maastro Clinic), Maastricht, The Netherlands.
⁵ Department of Clinical Oncology, The Christie NHS Foundation Trust & University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
⁶ Oncology Department, Vall d'Hebron University, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁷ Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain.
⁸ Thorax Institute, Institute Curie, Paris, France.
⁹ Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland.
¹⁰ Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
¹¹ Department of Radiation Oncology, Gustave Roussy, Villejuif, France.
¹² Université Claude Bernard Lyon1, and Hospices Civils de Lyon, Lyon, France.
¹³ Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
¹⁴ Department of Medical Oncology, Hospital Universitario 12 de Octubre, CNIO & Universidad Complutense, Madrid, Spain.
¹⁵ Department of Medical Oncology, Thoracic Group, Gustave Roussy, Villejuif, France.
¹⁶ Marsico Family Endowed Chair of Head and Neck Cancer Research, University of Colorado Cancer Center, Aurora, USA.
¹⁷ Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, USA.
¹⁸ LungenClinic, Airway Research Center North (ARCN), German Center for Lung Research, Grosshansdorf, Germany.
¹⁹ Egbert Smit, Department Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
²⁰ Chair Comprehensive Cancer Center Zürich, Universitätspital Zurich, Zurich, Switzerland.
²¹ Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
²² Cancer Evolution and Genome Stability Laboratory, The Francis Crick Institute and UCL Cancer Institute, UK.
²³ Lung Cancer Europe (LuCE), Bern, Switzerland.
²⁴ Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

PMID: 30624547
DOI: 10.1093/annonc/mdy553

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Drug Approval*
Expert Testimony
Humans
International Agencies
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Neoplasm Staging
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
durvalumab